|
Targeting Oncogenic RAS in Pediatric Leukemia |
Dana-Farber Cancer Institute |
Cure4Cam Childhood Cancer Foundation |
|
Physical Properties of Drug-Resistant Leukemia Cells |
Children’s Hospital Los Angeles |
Cure4Cam Childhood Cancer Foundation |
|
Identification and Targeting of Microenvironmental Factors Controlling Pediatric Leukemia |
New York University School of Medicine |
Cure4Cam Childhood Cancer Foundation |
|
Targeting Protein Translation to Antagonize MYC-driven Neuroblastoma |
Children’s Hospital of Philadelphia |
Cure4Cam Childhood Cancer Foundation |
|
Novel Approaches for Epigenetic Therapy for Relapsed Acute Lymphoblastic Leukemia |
The Johns Hopkins University School of Medicine |
Cure4Cam Childhood Cancer Foundation |
|
Natural Killer T cells with an IL-15-armored GD2-specific CAR for Children with Neuroblastoma |
Baylor College of Medicine |
Chance for Life, Cure4Cam Childhood Cancer Foundation, Tap Cancer Out, Turn It Gold |
|
CD47-blocking Oncolytic Vaccinia Viruses as Biotherapeutics for Pediatric Solid Tumors |
St. Jude Children’s Research Hospital |
Cure4Cam Childhood Cancer Foundation |
|
Targeting Microenvironmental Support of Acute Lymphoblastic Leukemia |
University of Rochester |
Cure4Cam Childhood Cancer Foundation |
|
Improving Immune-Mediated Oncolytic Viral Therapy: Engineering Tumor Vaccine Elements into the Virus |
Research Institute at Nationwide Children's Hospital |
Cure4Cam Childhood Cancer Foundation, Flashes of Hope |
|
Pharmacogenomics and Drug Screening Lead to a Novel Targeted Therapy with Potent and Specific Activity Against Mouse Models of MYCN-amplified Neuroblastoma |
Virginia Commonwealth University |
Cure4Cam Childhood Cancer Foundation, I Care I Cure |